摘要:
[Problems] The object is to improve the absorbability of a heterocyclic compound including s-triazine and a pyrimidine derivative in vitro. [Means for Solving Problems] Disclosed is, for example, an amorphous body of a heterocyclic compound as represented by the general formula (I) [wherein each of R's and others is as defined in the description] including s-triazine and a pyrimidine derivative, or a hydrate, a solvate or a pharmaceutically acceptable salt of the heterocyclic compound. Also disclosed is a process for producing the amorphous body. Further disclosed are: a solid dispersion comprising the amorphous body; and a medicinal preparation comprising the solid dispersion.
摘要:
[Problems] The object is to improve the absorbability of a heterocyclic compound including s-triazine and a pyrimidine derivative in vitro.[Means for Solving Problems] Disclosed is, for example, an amorphous body of a heterocyclic compound as represented by the general formula (I) [wherein each of R's and others is as defined in the description] including s-triazine and a pyrimidine derivative, or a hydrate, a solvate or a pharmaceutically acceptable salt of the heterocyclic compound. Also disclosed is a process for producing the amorphous body. Further disclosed are: a solid dispersion comprising the amorphous body; and a medicinal preparation comprising the solid dispersion.
摘要:
A novel method for immunosuppressive in a mammal suffering from an immune disease, including administering to the mammal a therapeutically effective amount of a heterocyclic compound represented by the general formula (I) (wherein X or other variables are as defined in the specification) or a pharmaceutically acceptable salt thereof is disclosed. A novel heterocyclic compound represented by the general formula (II) (wherein X or other variables are as defined in the specification) or a pharmaceutically acceptable salt thereof is also disclosed.
摘要:
Heterocyclic compounds in which s-triazine or pyrimidine is substituted with benzimidazole and morpholine and which are represented by the Formula I or phermaceutically acceptable acid addition salts thereof: wherein X and Y respectively represent nitrogen atom or one of them represents nitrogen atom and the other represents C—R7 wherein R7 represents hydrogen or halogen atom; R1, R2, R4, R5 and R6 represent hydrogen atom or C1-C6 alkyl; R3 represents morpholino, piperidino, piperazinyl, thiomorpholino, benzimidazolyl, cyano or the like.
摘要翻译:其中s-三嗪或嘧啶被苯并咪唑和吗啉取代的杂环化合物,其由式I表示或其药学上可接受的酸加成盐:其中X和Y分别表示氮原子或其中一个表示氮原子,另一个表示 C-R7,其中R7表示氢或卤素原子; R1,R2,R4,R5和R6表示氢原子或C1-C6烷基; R 3表示吗啉代,哌啶子基,哌嗪基,硫代吗啉代,苯并咪唑基,氰基等。
摘要:
A novel method for immunosuppressive in a mammal suffering from an immune disease, including administering to the mammal a therapeutically effective amount of a heterocyclic compound represented by the general formula (I) (wherein X or other variables are as defined in the specification) or a pharmaceutically acceptable salt thereof is disclosed. A novel heterocyclic compound represented by the general formula (II) (wherein X or other variables are as defined in the specification) or a pharmaceutically acceptable salt thereof is also disclosed.
摘要:
The present invention relates to heterocyclic compounds represented by the formula I or pharmaceutically acceptable salts thereof and antitumor agents containing the heterocyclic compounds as effective components: wherein X represents nitrogen atom or CH; R1 represents CHnF3-n (wherein n is 1 or 2), hydroxy C1-C6 alkyl, NHR6 [wherein R6 represents hydrogen atom or COR (wherein R represents hydrogen atom, C1-C6 alkyl or C1-C6 alkoxy)]; R2 represents morpholino (which may be substituted with one to four C1-C6 alkyl), thiomorpholino, piperidino, pyrrolidinyl (which may be substituted with hydroxy C1-C6 alkyl), oxazolidinyl (which may be substituted with one or two C1-C6 alkyl) or tetrahydro-1,4-thiazin-1-oxo-4-yl; R3 and R4 each represent hydrogen atom or C1-C6 alkyl; and R5 represents hydrogen atom, amino or hydroxyl.
摘要翻译:本发明涉及由式I表示的杂环化合物或其药学上可接受的盐和含有杂环化合物作为有效成分的抗肿瘤剂:其中X表示氮原子或CH; R 1表示CH 3 N 3-n N(其中n为1或2),羟基C 1 - C 6 -C 6烷基,NHR 6 [其中R 6表示氢原子或COR(其中R表示氢原子,C 1〜 C 1 -C 6烷基或C 1 -C 6烷氧基)]; R 2表示吗啉代(其可以被一至四个C 1 -C 6烷基取代),硫代吗啉代,哌啶子基,吡咯烷基(其可以 被羟基C 1 -C 6烷基取代),恶唑烷基(其可以被一个或两个C 1 -C 6烷基取代) C 6烷基)或四氢-1,4-噻嗪-1-氧代-4-基; R 3和R 4各自表示氢原子或C 1 -C 6烷基; R 5表示氢原子,氨基或羟基。
摘要:
The present invention relates to heterocyclic compounds represented by the formula I or pharmaceutically acceptable salts thereof and antitumor agents containing the heterocyclic compounds as effective components: wherein X represents nitrogen atom or CH; R1 represents CHnF3-n (wherein n is 1 or 2), hydroxy C1-C6 alkyl, NHR6 [wherein R6 represents hydrogen atom or COR (wherein R represents hydrogen atom, C1-C6 alkyl or C1-C6 alkoxy)]; R2 represents morpholino (which may be substituted with one to four C1-C6 alkyl), thiomorpholino, piperidino, pyrrolidinyl (which may be substituted with hydroxy C1-C6 alkyl), oxazolidinyl (which may be substituted with one or two C1-C6 alkyl) or tetrahydro-1,4-thiazin-1-oxo-4-yl; R3 and R4 each represent hydrogen atom or C1-C6 alkyl; and R5 represents hydrogen atom, amino or hydroxyl.
摘要翻译:本发明涉及由式I表示的杂环化合物或其药学上可接受的盐和含有杂环化合物作为有效成分的抗肿瘤剂:其中X表示氮原子或CH; R 1表示CH 3 N 3-n N(其中n为1或2),羟基C 1 - C 6 -C 6烷基,NHR 6 [其中R 6表示氢原子或COR(其中R表示氢原子,C 1〜 C 1 -C 6烷基或C 1 -C 6烷氧基)]; R 2表示吗啉代(其可以被一至四个C 1 -C 6烷基取代),硫代吗啉代,哌啶子基,吡咯烷基(其可以 被羟基C 1 -C 6烷基取代),恶唑烷基(其可以被一个或两个C 1 -C 6烷基取代) C 6烷基)或四氢-1,4-噻嗪-1-氧代-4-基; R 3和R 4各自表示氢原子或C 1 -C 6烷基; R 5表示氢原子,氨基或羟基。
摘要:
The present invention relates to heterocyclic compounds represented by the formula I or pharmaceutically acceptable salts thereof and antitumor agents containing the heterocyclic compounds as effective components: wherein X represents nitrogen atom or CH; R1 represents CHnF3-n (wherein n is 1 or 2), hydroxy C1–C6 alkyl, NHR6 [wherein R6 represents hydrogen atom or COR (wherein R represents hydrogen atom, C1–C6 alkyl or C1–C6 alkoxy)]; R2 represents morpholino (which may be substituted with one to four C1–C6 alkyl), thiomorpholino, piperidino, pyrrolidinyl (which may be substituted with hydroxy C1–C6 alkyl), oxazolidinyl (which may be substituted with one or two C1–C6 alkyl) or tetrahydro-1,4-thiazin-1-oxo-4-yl; R3 and R4 each represent hydrogen atom or C1–C6 alkyl; and R5 represents hydrogen atom, amino or hydroxyl.
摘要翻译:本发明涉及由式I表示的杂环化合物或其药学上可接受的盐和含有杂环化合物作为有效成分的抗肿瘤剂:其中X表示氮原子或CH; R 1表示CH 3 N 3-n N(其中n为1或2),羟基C 1 - C 6 -C 6烷基,NHR 6 [其中R 6表示氢原子或COR(其中R表示氢原子,C 1〜 C 1 -C 6烷基或C 1 -C 6烷氧基)]; R 2表示吗啉代(其可以被一至四个C 1 -C 6烷基取代),硫代吗啉代,哌啶子基,吡咯烷基(其可以 被羟基C 1 -C 6烷基取代),恶唑烷基(其可以被一个或两个C 1 -C 6烷基取代) C 6烷基)或四氢-1,4-噻嗪-1-氧代-4-基; R 3和R 4各自表示氢原子或C 1 -C 6烷基; R 5表示氢原子,氨基或羟基。
摘要:
A novel method for immunosuppressive in a mammal suffering from an immune disease, including administering to the mammal a therapeutically effective amount of a heterocyclic compound represented by the general formula (I) (wherein X or other variables are as defined in the specification) or a pharmaceutically acceptable salt thereof is disclosed. A novel heterocyclic compound represented by the general formula (II) (wherein X or other variables are as defined in the specification) or a pharmaceutically acceptable salt thereof is also disclosed.
摘要:
The present application describes a method of treating prostate cancer, melanoma or hepatic cancer in a subject in need thereof, the method comprising administering to said subject a therapeutically effective amount of the heterocyclic compound represented by Formula I or its pharmaceutically acceptable salt: